The Institute for Clinical and Economic Review (ICER) on Friday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for moderate-to-severe plaque psoriasis. The review will be open to public comment until May 25.
Findings contained in this report are preliminary and subject to change based on additional stakeholder input and further analysis of data.
ICER previously reviewed treatments for plaque psoriasis in 2016. In addition to incorporating emerging clinical data for previously reviewed therapies, this condition update report includes new analyses of guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), certolizumab pegol (Cimzia, UCB), and risankizumab (AbbVie). Certolizumab pegol is currently approved for use in several other indications, including rheumatoid arthritis, and an approval decision for its plaque psoriasis indication is expected in May 2018. Risankizumab was added to the scope of the review based on feedback received during conversations with manufacturers and clinical experts. The drug has not yet been filed for FDA review.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. During this review update, ICER spoke with key patient groups, clinical experts, and manufacturers of drugs not included in ICER’s initial review. Public comments were also accepted on a Draft Scoping Document. The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.